United States Patent 10,111,890: Omadacycline ABSSSI Dosing Claims, Patent Scope, and Competitive Landscape

U.S. Patent No. 10,111,890 protects a specific oral omadacycline regimen for treating bacterial skin and skin structure infections, including acute bacterial skin and skin structure infections (ABSSSI). The core regimen is 450 mg once daily for two days, followed by 300 mg once daily for at least five additional days. The patent also covers specified infection types, pathogens, fasting administration, treatment duration, pharmacokinetic exposure, tolerability outcomes, and 150 mg tablet administration.[1]

The patent is a method-of-treatment patent. It does not claim the underlying omadacycline molecule broadly, nor does it independently claim every oral omadacycline formulation. Its commercial significance depends on whether a generic or other competitor markets oral omadacycline for ABSSSI using the claimed loading and maintenance schedule.

What drug and therapeutic regimen does U.S. Patent 10,111,890 cover?

The claimed active ingredient is 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline, commonly known as omadacycline. The marketed product is Nuzyra, developed and commercialized by Paratek Pharmaceuticals.[2]

The independent claim requires each of the following elements:

Claim element	Requirement
Patient	Human subject needing treatment
Disease	Bacterial skin or skin structure infection
Active ingredient	Omadacycline or a salt
Route	Oral administration
Loading dose	About 450 mg per day for two consecutive days
Maintenance dose	About 300 mg per day for five or more days
Result	The subject is treated

The claim is therefore narrower than a claim covering oral omadacycline generally. A product or treatment protocol that omits the 450 mg loading phase, uses a materially different maintenance dose, or is directed to a non-covered disease could fall outside literal infringement of claim 1, subject to equivalents and other patent claims.

The patent claims a therapeutic dosing method, not merely the administration of a tablet. In a generic-drug context, infringement analysis would focus on the proposed label, prescribing instructions, product design, promotional materials, and whether the generic applicant seeks approval for the patented ABSSSI regimen.

What are the dependent claims in U.S. Patent 10,111,890?

The dependent claims add disease categories, administration conditions, dosing frequency, treatment duration, pathogens, pharmacokinetics, safety outcomes, and tablet strength.

Disease and infection limitations

Claims 2 through 6 narrow the infection population to:

Wound infection
Cellulitis or erysipelas
Major abscess
Furuncles or boils
Carbuncle
Staphylococcal scalded skin syndrome
Ecthyma
ABSSSI
Community-acquired ABSSSI
Infections associated with trauma, surgery, or intravenous drug use

Claim 3 is commercially important because Nuzyra is FDA-approved for treatment of ABSSSI in adults. The FDA labeling describes oral and intravenous omadacycline regimens for ABSSSI and community-acquired bacterial pneumonia.[2]

Administration and duration limitations

Claims 7 and 8 require or specify:

Administration under fasting conditions
Once-daily administration

Claim 9 covers treatment periods up to approximately 14, 10, 9, 8, 7, or 5 days. Claim 10 specifically identifies seven-to-10-day treatment.

These limitations track the clinical dosing pattern for oral Nuzyra. They also create potential design-around questions. A competitor could evaluate whether a different treatment duration, dosing interval, or administration condition avoids a particular dependent claim while still implicating claim 1.

Salt and dosage-form limitations

Claim 11 covers a tosylate salt of omadacycline.

Claim 17 requires each dose to be administered as 150 mg tablets. The commercial consequence is significant because the claimed 450 mg loading dose corresponds to three 150 mg tablets, while the 300 mg maintenance dose corresponds to two 150 mg tablets.

The claim does not appear to require a specific inactive-ingredient composition, coating, dissolution profile, packaging configuration, or release mechanism. Those subjects would generally be addressed by separate formulation or composition claims if present in related patents.

Pathogen limitations

Claim 12 covers specified Gram-positive pathogens, including:

Staphylococcus aureus
Staphylococcus lugdunensis
Streptococcus species
Enterococcus species
Streptococcus anginosus group
Viridans group streptococci
Clostridium perfringens
Finegoldia magna

Claim 13 further identifies MRSA, MSSA, Streptococcus pyogenes, Streptococcus anginosus group organisms, and vancomycin-susceptible Enterococcus faecalis.

Claim 14 covers specified Gram-negative organisms, including:

Enterobacter cloacae
Escherichia coli
Klebsiella pneumoniae
Prevotella denticola
Prevotella melaninogenica

The pathogen claims are narrower than the independent claim. They may be relevant in litigation where microbiological data, diagnostic records, or prescribing rationale establish the organism causing the infection.

How broad is claim 1 of U.S. Patent 10,111,890?

Claim 1 is a regimen-specific method claim with a relatively concentrated infringement profile.

It covers oral treatment of a human bacterial skin or skin structure infection using omadacycline or a salt, provided the regimen includes approximately 450 mg daily for two days followed by approximately 300 mg daily for at least five additional days.

The claim does not expressly require:

A particular bacterial species
Community-acquired infection
A specified tablet strength
Fasting administration
A seven-to-10-day total course
A particular clinical severity score
Monotherapy
A particular formulation excipient
A particular pharmacokinetic result

Those subjects appear in dependent claims or are not required by the claim language.

Claim construction issues

Several terms could affect enforcement:

"About 450 mg" and "about 300 mg."
Courts generally assess "about" in view of the specification, prosecution history, and technical context. The practical scope may include ordinary manufacturing and dosing variation, but the patent does not establish an unlimited range.
"For five or more days."
The maintenance period has a minimum duration. A five-day maintenance course is within claim 1; shorter maintenance treatment may not satisfy the literal limitation.
"Such that said subject is treated."
This result limitation may require successful treatment, depending on claim construction. In a drug-label case, the intended method of use and claimed therapeutic purpose can be more important than whether every patient responds.
"Orally administering."
The claim excludes an exclusively intravenous regimen. A product with both intravenous and oral dosing may still raise infringement issues if the labeled or actual method includes the claimed oral sequence.
"Omadacycline or a salt thereof."
Claim 1 is not limited to the tosylate salt. Claim 11 separately identifies the tosylate salt, but the independent claim reaches the active compound and salts generally, subject to claim construction and written-description limitations.

What patents protect Nuzyra and omadacycline?

Nuzyra has a patent estate extending beyond the dosing claims in U.S. Patent 10,111,890. The estate can be divided into four technical groups:

Patent category	Protected subject matter	Commercial purpose
Active pharmaceutical ingredient	Omadacycline and related aminomethyl tetracycline compounds	Protects the molecule or chemical genus
Pharmaceutical composition	Omadacycline salts, tablets, dosage forms, and excipient systems	Protects product formulation
Method of treatment	ABSSSI, community-acquired infections, pneumonia, and dosing regimens	Protects clinical use and labeling
Manufacturing and formulation process	Preparation, purification, solid forms, or dosage-form manufacture	Creates production barriers and alternative infringement risks

U.S. Patent 10,111,890 is primarily in the third category. Its strongest commercial position is against an oral generic that copies the Nuzyra ABSSSI dosing schedule.

The exact Orange Book listing and expiration dates for all Nuzyra patents must be distinguished from the statutory term of the individual patent. FDA Orange Book listings identify patents submitted by the NDA holder, but they do not themselves resolve validity, enforceability, claim construction, or infringement.[3]

When does U.S. Patent 10,111,890 expire?

The patent issued on October 30, 2018.[1] Its patent term is governed by the earliest applicable nonprovisional or international filing date in the priority chain, not simply by the issue date. Based on the patent family priority information, the nominal term is expected to extend into approximately 2035, subject to patent-term adjustment, terminal disclaimers, patent-term extension, and the controlling filing history.

The relevant commercial timing is therefore:

Event	Date or period
Earliest disclosed priority	June 30, 2014 provisional priority
International or nonprovisional family filing	2015 family period
U.S. patent issuance	October 30, 2018
Nominal patent term	Approximately through June 2035, subject to USPTO term calculation
FDA approval of Nuzyra	March 19, 2018
FDA chemical exclusivity for a new chemical entity	Five years from approval, subject to statutory exceptions
ABSSSI and CABP commercial launch period	2018 onward

The June 30, 2035 estimate should not be treated as an Orange Book expiration date without checking the current USPTO maintenance and patent-term records. A terminal disclaimer or a patent-term adjustment could change the operative date.

What is the Orange Book status of U.S. Patent 10,111,890?

Nuzyra is an FDA-approved small-molecule drug, not a biologic. Its principal regulatory pathway is an NDA, not a BLA. The relevant FDA exclusivity and patent framework is therefore the Orange Book and Hatch-Waxman abbreviated new drug application process.[2][3]

A patent listed for an approved drug can create a Paragraph IV certification issue for a generic applicant. A generic applicant may certify that the listed patent is invalid, unenforceable, or will not be infringed. If the NDA holder sues within the statutory period, the ANDA approval may be stayed for up to 30 months, subject to statutory exceptions and court developments.[4]

For U.S. Patent 10,111,890, the commercial questions are:

Whether the patent is currently listed against the relevant Nuzyra indication or dosage form
Whether the patent’s use code covers ABSSSI treatment
Whether a generic applicant makes a Paragraph IV certification
Whether the applicant seeks a section viii statement carving out the patented use
Whether the proposed label includes the 450 mg loading and 300 mg maintenance schedule

A label carve-out may be difficult if the patented ABSSSI regimen is central to the approved oral use. The feasibility of a section viii carve-out depends on the precise FDA use code and the remaining non-patented indications.

Are there Paragraph IV challenges to omadacycline patents?

A Paragraph IV challenge would be the principal generic pathway for attacking listed Nuzyra patents before expiration. The challenge could assert:

Lack of novelty
Obviousness of the loading and maintenance regimen
Lack of written description
Lack of enablement
Indefiniteness of terms such as "about"
Noninfringement based on a different regimen or label
Invalidity of dependent claims directed to pharmacokinetic or tolerability outcomes

The supplied patent claims create different challenge profiles. Claim 1 is vulnerable to prior-art arguments directed to omadacycline dosing and ABSSSI treatment. Claims 16 and 17 may present different issues because they require a pharmacokinetic exposure or a specific tablet presentation.

No Paragraph IV outcome can be inferred from the patent text alone. A definitive assessment requires the ANDA applicant’s certification, any notice letter, district-court complaint, docket activity, and later settlement terms. The patent itself does not disclose whether a generic applicant has challenged the claims.

What patent litigation affects U.S. Patent 10,111,890?

The principal litigation risk is an ANDA case under the Hatch-Waxman framework. A generic applicant could challenge the patent before commercial launch, and Paratek or the relevant patent owner could seek an injunction.

Potential litigation issues include:

Issue	Relevance
Infringement	Whether the proposed generic label instructs the claimed oral regimen
Induced infringement	Whether the generic label encourages physicians or patients to use the regimen
Claim construction	Meaning of "about," "treated," and the dose sequence
Obviousness	Whether prior art made the two-day loading regimen predictable
Written description	Whether the specification supports the full breadth of pathogen and infection claims
Enablement	Whether the disclosure supports treatment across the claimed infections
Damages	Lost sales, reasonable royalty, or other statutory remedies
Injunction	Whether launch is blocked before patent expiration

A settlement could permit an agreed generic launch date before patent expiration. Such an agreement may include a license, authorized generic arrangement, supply agreement, or other commercial terms. No settlement terms should be assumed without a filed agreement, court docket, or FTC disclosure.

How strong is the patent estate for omadacycline?

The estate has moderate-to-strong commercial value if several conditions hold:

The patent remains enforceable through the expected 2035 term.
The FDA-approved oral ABSSSI label requires or closely tracks the patented dosing sequence.
The listed claims cover the generic label rather than only off-label use.
Related formulation or composition patents cover the commercial tablet.
No competing product provides a clinically accepted substitute with comparable spectrum and dosing convenience.

U.S. Patent 10,111,890 is strongest against a copycat oral ABSSSI product using the standard Nuzyra schedule. It is weaker against:

Intravenous-only products
Alternative omadacycline regimens
Products marketed for indications outside the listed use
Products that omit the patented loading sequence
Formulations that do not use the claimed 150 mg tablet presentation, for purposes of claim 17

The estate is not equivalent to a broad molecule patent. If the underlying compound claims have earlier expirations or validity constraints, the later method patents become more important for market exclusivity.

What generic launch scenarios exist for Nuzyra?

Scenario 1: Paragraph IV challenge with litigation

A generic applicant files an ANDA with a Paragraph IV certification. Paratek sues within the statutory period. FDA approval may be delayed by the statutory stay, while the district court evaluates validity and infringement.

This scenario creates the greatest near-term uncertainty but may produce a court decision before 2035.

Scenario 2: Section viii label carve-out

The applicant removes the patented ABSSSI use from its label and seeks approval for a non-patented use or route. The commercial value depends on whether the remaining label supports meaningful prescriptions without inducing the patented use.

Scenario 3: Non-infringing dosing design

The applicant uses a different dosing schedule, dose strength, or treatment duration. This approach must account for other method, formulation, and composition patents. A change that avoids claim 1 may still infringe a dependent claim or a related patent.

Scenario 4: Settlement or licensed entry

The applicant agrees to a delayed entry date, licensed launch, or authorized generic arrangement. The entry date would depend on the settlement’s patent and commercial provisions.

Scenario 5: Post-expiration launch

The applicant waits for the relevant patent and regulatory exclusivity periods to expire. This eliminates litigation exposure but delays market entry.

Is there biosimilar risk for Nuzyra?

There is no biosimilar pathway for Nuzyra because omadacycline is a chemically synthesized small-molecule drug. Competitive entry would proceed through an ANDA or, in some cases, a 505(b)(2) application rather than a biosimilar application under the Public Health Service Act.[2][5]

The principal competitive risks are therefore:

Generic omadacycline tablets
Alternative tetracycline-class antibiotics
Fluoroquinolones, beta-lactams, glycopeptides, and other ABSSSI therapies
Hospital formulary substitution
Intravenous-to-oral treatment alternatives
New agents targeting resistant Gram-positive pathogens

How does the patent compare with other antibiotic exclusivity strategies?

Protection strategy	Example relevance to Nuzyra	Entry risk
New chemical entity exclusivity	Applied to initial FDA approval	Ends earlier than long-dated method patents
Composition-of-matter patent	Protects omadacycline molecule or salt	Usually strongest claim category
Formulation patent	Protects tablet or delivery system	Can block product copying
Method-of-treatment patent	U.S. 10,111,890	Depends heavily on label and actual use
Orphan-drug exclusivity	Not the principal Nuzyra framework	Limited relevance to ABSSSI
Patent-term extension	May apply only to qualifying patent and regulatory period	Requires FDA and USPTO confirmation
Biosimilar exclusivity	Not applicable	No biologic pathway

What manufacturing and IP barriers remain after the dosing patent?

A competitor may need to address more than the dosing method. Key barriers include:

Synthesis of the aminomethyl tetracycline active ingredient
Control of impurities and stereochemical composition
Salt selection and solid-state properties
Tablet compression and stability
Bioequivalence under fasting conditions
Food-effect characterization
CMC documentation for an ANDA
Potential formulation, process, and composition patents
Patent certifications across the complete Orange Book listing

The fasting limitation in claim 7 is commercially relevant because oral omadacycline exposure is affected by food and administration conditions. FDA labeling instructs patients on administration requirements, making the fasting condition more likely to appear in product-use instructions.[2]

Key Takeaways

U.S. Patent 10,111,890 covers oral omadacycline treatment of bacterial skin and skin structure infections.
Claim 1 requires approximately 450 mg daily for two days, followed by approximately 300 mg daily for at least five additional days.
The patent is a method-of-treatment patent, not a broad composition-of-matter patent.
Dependent claims cover ABSSSI, community-acquired ABSSSI, specified pathogens, fasting administration, once-daily use, treatment duration, tosylate salt, AUC exposure, and 150 mg tablets.
The patent issued October 30, 2018, with a family-based nominal term expected to extend to approximately June 2035, subject to the official USPTO term calculation.
Generic risk will depend on Paragraph IV certifications, use-code scope, label carve-outs, and related formulation or composition patents.
Nuzyra has no biosimilar risk because omadacycline is a small-molecule drug.
The patent is commercially strongest against a generic oral product that copies the FDA-aligned ABSSSI loading and maintenance regimen.

FAQs

Does U.S. Patent 10,111,890 cover intravenous omadacycline?

No. The independent claims require oral administration. An exclusively intravenous regimen would not satisfy the oral-administration limitation, although other patents could cover intravenous formulations or treatment methods.

Does the patent cover all uses of omadacycline?

No. The claims focus on bacterial skin and skin structure infections and related ABSSSI treatment. The patent does not claim every indication, dose, route, or formulation of omadacycline.

Can a generic avoid claim 17 by using 100 mg or 300 mg tablets?

Potentially, but avoiding claim 17 would not necessarily avoid claim 1 or other patents. Claim 1 is not expressly limited to 150 mg tablets.

Does a five-day course infringe the patent?

A regimen with two loading days followed by at least five maintenance days can satisfy claim 1. The total course would be at least seven days under that structure.

Is omadacycline protected by a biosimilar exclusivity period?

No. Omadacycline is a small-molecule active ingredient regulated through the NDA and ANDA framework. Biosimilar exclusivity provisions do not apply.

References

U.S. Patent No. 10,111,890, “Methods of treating bacterial infections.” U.S. Patent and Trademark Office. Issued October 30, 2018.
U.S. Food and Drug Administration. (2018). Nuzyra (omadacycline) prescribing information.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book.
U.S. Food and Drug Administration. (2024). Abbreviated new drug application approvals and patent certifications.
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Paratek Pharms	NUZYRA	omadacycline tosylate	TABLET;ORAL	209816-001	Oct 2, 2018		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				TREATMENT OF SUBJECTS HAVING BACTERIAL SKIN OR SKIN STRUCTURE INFECTION	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2017305409	⤷ Start Trial
Australia	2022203977	⤷ Start Trial
Australia	2024205530	⤷ Start Trial
Australia	2026208000	⤷ Start Trial
Brazil	112019001948	⤷ Start Trial
Canada	3031790	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 10,111,890

Which drugs does patent 10,111,890 protect, and when does it expire?

Summary for Patent: 10,111,890